Education
About Us
Working with TipRanks
Follow Us
Anebulo Pharmaceuticals (ANEB)
NASDAQ:ANEB
ANEB Stock Chart & Stats
$1.72
-$0.06(-3.96%)
At close: 4:00 PM EST
$1.72
-$0.06(-3.96%)
Day’s Range― - ―
52-Week Range$0.80 - $3.42
Previous CloseN/A
Volume2.65K
Average Volume (3M)16.98K
Market Cap
$89.15M
Enterprise Value$92.36M
Total Cash (Recent Filing)$10.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding41,084,732
10 Day Avg. Volume7,376
30 Day Avg. Volume16,982
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-7.67
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Corporate StrategyBoard approves plan to go private at a 91% premium to previous close.
Bears Say
Stock PriceThe upside potential is limited as the shares approach the transaction price and exceed the 12-month price target.
Stock RatingStock rating downgraded to Hold.
Anebulo Pharmaceuticals News
ANEB FAQ
What was Anebulo Pharmaceuticals’s price range in the past 12 months?
Anebulo Pharmaceuticals lowest stock price was $0.80 and its highest was $3.42 in the past 12 months.
What is Anebulo Pharmaceuticals’s market cap?
Anebulo Pharmaceuticals’s market cap is $89.15M.
When is Anebulo Pharmaceuticals’s upcoming earnings report date?
Anebulo Pharmaceuticals’s upcoming earnings report date is Feb 06, 2026 which is in 44 days.
How were Anebulo Pharmaceuticals’s earnings last quarter?
Anebulo Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.07.
Is Anebulo Pharmaceuticals overvalued?
According to Wall Street analysts Anebulo Pharmaceuticals’s price is currently Overvalued.
Does Anebulo Pharmaceuticals pay dividends?
Anebulo Pharmaceuticals does not currently pay dividends.
What is Anebulo Pharmaceuticals’s EPS estimate?
Anebulo Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anebulo Pharmaceuticals have?
Anebulo Pharmaceuticals has 41,084,732 shares outstanding.
What happened to Anebulo Pharmaceuticals’s price movement after its last earnings report?
Anebulo Pharmaceuticals reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -3.797%.
Which hedge fund is a major shareholder of Anebulo Pharmaceuticals?
Currently, no hedge funds are holding shares in ANEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anebulo Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.14%
12-Months-Change
Fundamentals
Return on Equity
-145.11%
Trailing 12-Months
Asset Growth
333.60%
Trailing 12-Months
Company Description
Anebulo Pharmaceuticals
Anebulo Pharmaceuticals (ANEB) is a clinical-stage biotechnology company focused on developing novel treatments for patients suffering from cannabinoid overdose and substance addiction. The company primarily operates within the pharmaceutical and biotechnology sectors, targeting unmet medical needs related to the growing marijuana and cannabinoid markets. Anebulo's lead product candidate, ANEB-001, is an orally administered small molecule designed to treat acute cannabinoid intoxication.
Technical Analysis
VistaGen Therapeutics
―
Beyondspring
―
Surrozen
―
Context Therapeutics
―
Alto Neuroscience, Inc.
―